Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC

Ricardo A. Rendon

doi:10.5489/CUAJ.6388

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC

Ricardo A. Rendon

Engineering

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Original language	English
Journal	Journal of the Canadian Urological Association
Volume	14
Issue number	12
DOIs	https://doi.org/10.5489/CUAJ.6388
Publication status	Published - Jun 2020

ASJC Scopus Subject Areas

Oncology
Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5489/CUAJ.6388

Fingerprint

Dive into the research topics of 'Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC'. Together they form a unique fingerprint.

Cite this

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC. / Rendon, Ricardo A.
In: Journal of the Canadian Urological Association, Vol. 14, No. 12, 06.2020.

Research output: Contribution to journal › Article › peer-review

@article{751e0e50a4e14e0d8eee56608955f4be,

title = "Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC",

author = "Rendon, {Ricardo A.}",

note = "Publisher Copyright: {\textcopyright} 2020 Canadian Urological Association",

year = "2020",

month = jun,

doi = "10.5489/CUAJ.6388",

language = "English",

volume = "14",

journal = "Journal of the Canadian Urological Association",

issn = "1911-6470",

publisher = "Canadian Medical Association",

number = "12",

}

TY - JOUR

T1 - Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada

T2 - Final results of COSMiC

AU - Rendon, Ricardo A.

PY - 2020/6

Y1 - 2020/6

UR - http://www.scopus.com/inward/record.url?scp=85090450609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090450609&partnerID=8YFLogxK

U2 - 10.5489/CUAJ.6388

DO - 10.5489/CUAJ.6388

M3 - Article

AN - SCOPUS:85090450609

SN - 1911-6470

VL - 14

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

IS - 12

ER -

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this